AbbVie acquires cancer drugmaker Pharmacyclics for $21bn
With the acquisition, AbbVie will now have access to Pharmacyclics’ Imbruvic11a (ibrutinib), a Bruton’s tyrosine kinase (BTK) inhibitor used to treat hematological cancers. Imbruvica is approved for use